Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21346049 | 0.88 | ALDH1A1 (0.32) | ALDH1A1RXFP1 | |
| SCHEMBL24781048 | 0.86 | ALDH1A1 (0.40) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24781018 | 0.86 | ALDH1A1 (0.35) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24780302 | 0.85 | ALDH1A1 (0.34) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24780873 | 0.84 | ALDH1A1 (0.34) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24780839 | 0.84 | ALDH1A1 (0.34) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24781001 | 0.84 | ALDH1A1 (0.34) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL24780875 | 0.84 | P2RY2 (0.34) | ALDH1A1RXFP1P2RX1P2RX3P2RX4 | |
| SCHEMBL21345593 | 0.83 | MEN1 (0.36) | ALDH1A1LMNATDP1CCNT1CCNK | |
| SCHEMBL21055674 | 0.83 | MEN1 (0.36) | ALDH1A1LMNATDP1CCNT1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025938-A1 | NOVEL FORMS OF ANTIVIRAL NUCLEOSIDES | MERCK SHARP & DOHME LLC | 2024-01-25 | — | — | US | disclosed |
| US-20240025938-A1 | NOVEL FORMS OF ANTIVIRAL NUCLEOSIDES | MERCK SHARP & DOHME LLC | 2024-01-25 | — | — | US | disclosed |
| WO-2023070058-A1 | TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES | MERCK SHARP & DOHME LLC (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-19 | — | — | US | disclosed |
| WO-2021159044-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021137913-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2019173602-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | ALDH1A1 1847/4885RXFP1 3082/4885P2RX1 215/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | ALDH1A1 1480/4885RXFP1 4134/4885P2RX1 246/4885 |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | TYMP, MTAP, DCTD | ALDH1A1 2860/4885RXFP1 4802/4885P2RX1 622/4885 |
| US-20240025938-A1 | NOVEL FORMS OF ANTIVIRAL NUCLEOSIDES | UMPS, UPP1, UCK2 | ALDH1A1 1431/4885RXFP1 2682/4885P2RX1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.